Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1

https://doi.org/10.18632/oncotarget.2529 Verena Wagner, Dirk Hose, Anja Seckinger, Ludmila Weiz, Tobias Meißner, Thiery Rème, Iris Breitkreutz, Klaus Podar, Anthony D. Ho, Hartmut Goldschmidt, Alwin...

Bibliographic Details

Main Authors:	Wagner, Verena (Author) , Hose, Dirk (Author) , Seckinger, Anja (Author) , Weiz, Ludmila (Author) , Meißner, Tobias (Author) , Breitkreutz, Iris (Author) , Podar, Klaus (Author) , Ho, Anthony Dick (Author) , Goldschmidt, Hartmut (Author) , Krämer, Alwin (Author) , Raab, Marc-Steffen (Author)
Format:	Article (Journal)
Language:	English
Published:	September 26, 2014
In:	OncoTarget Year: 2014, Volume: 5, Issue: 21, Pages: 10237-10250
ISSN:	1949-2553
DOI:	10.18632/oncotarget.2529
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.18632/oncotarget.2529 Verlag, lizenzpflichtig, Volltext: https://www.oncotarget.com/article/2529/text/
Author Notes:	Verena Wagner, Dirk Hose, Anja Seckinger, Ludmila Weiz, Tobias Meißner, Thiery Rème, Iris Breitkreutz, Klaus Podar, Anthony D. Ho, Hartmut Goldschmidt, Alwin Krämer, Bernard Klein and Marc S. Raab